


# Vasculiti dei piccoli vasi e vasculiti ANCA – associati

23° corso di aggiornamento per  
medici di base

Diego Kyburz  
Rheumatologie  
Universitätsspital Basel



# Case

36 yrs old female

## History:

- Good health, no relevant diseases or operations

## Presenting problem

- New skin rash and pain in the ankle
- Since 3 weeks sore throat
- Medication: NSAID

# Case

## Examination

- Afebrile, BP normal, normal cardiopulmonary auscultation
- inflamed throat, no pus
- Ankles bilaterally tender on palpation, no synovitis



# Case



# Case

|         |  |                      |               |                      |
|---------|--|----------------------|---------------|----------------------|
| 8.59    |  | Leukozyten           | 3.50 - 10.00  | x10 <sup>9</sup> /l  |
| 3.75 -  |  | Erythrozyten         | 4.20 - 5.40   | x10 <sup>12</sup> /l |
| 113 -   |  | Hämoglobin           | 120 - 160     | g/l                  |
| 0.33 -  |  | Hämatokrit           | 0.36 - 0.46   | l/l                  |
| 89      |  | - MCV                | 79 - 95       | fl                   |
| 30.2    |  | - MCH                | 27.0 - 33.2   | pg                   |
| 339     |  | - MCHC               | 320 - 360     | g/l                  |
| 12.8    |  | - EVB                | 11.5 - 14.5   | %                    |
| 0.3     |  | - hypochrome Ec      | <5.0          | %                    |
| 436     |  | Thrombozyten         | 150 - 450     | x10 <sup>9</sup> /l  |
| 9       |  | - MTV                | 6-10          | fl                   |
|         |  | Retikulozyten        |               | ‰                    |
|         |  | - absolut            |               | x10 <sup>9</sup> /l  |
|         |  | - reife              |               | %                    |
|         |  | - unreife            |               | %                    |
|         |  | - CHR                |               | pg                   |
| 5.248   |  | Neutroph.abs.(Seg+St | 1.300 - 6.700 | x10 <sup>9</sup> /l  |
| 2.208   |  | Lymphozyten          | 0.900 - 3.300 | x10 <sup>9</sup> /l  |
| 0.696 + |  | Monozyten            | 0.120 - 0.620 | x10 <sup>9</sup> /l  |
| 0.155   |  | Eosinophile          | 0 - 0.300     | x10 <sup>9</sup> /l  |
| 0.069   |  | Basophile            | 0 - 0.090     | x10 <sup>9</sup> /l  |
| 0.215   |  | LUC                  | 0 - 0.310     | x10 <sup>9</sup> /l  |
| 4174    |  | Arbeitsplatz ID      |               |                      |
| 4       |  | Blutsenkung          | 0 - 28        | mm/1Std              |

|        |  |                          |           |             |
|--------|--|--------------------------|-----------|-------------|
| 138    |  | Natrium                  | 135-145   | mmol/l      |
| 3.8    |  | Kalium                   | 3.6-4.8   | mmol/l      |
| 105    |  | Chlorid                  | 97-110    | mmol/l      |
| 77     |  | Kreatinin                | 42-80     | µmol/l      |
| 86*    |  | GFR geschätzt (CKD-EPI)  |           | ml/min/1.73 |
| 3.9    |  | Harnstoff                | 2.6-6.7   | mmol/l      |
| 10     |  | Bilirubin                | <15       | µmol/l      |
| 12     |  | ASAT                     | 11-34     | U/l         |
| 9      |  | ALAT                     | 8-41      | U/l         |
| 10     |  | GGT                      | 6-40      | U/l         |
| 54     |  | alk. Phosphatase         | 35-105    | U/l         |
| 2.09 - |  | Calcium                  | 2.10-2.65 | mmol/l      |
| 2.36*  |  | Albumin korrig. Calcium  | 2.10-2.65 | mmol/l      |
| 1.20   |  | Phosphat                 | 0.80-1.50 | mmol/l      |
|        |  | Magnesium                |           | mmol/l      |
| 154 -  |  | Harnsäure                | 173-359   | µmol/l      |
|        |  | Triglyzeride             |           | mmol/l      |
|        |  | Cholesterin              |           | mmol/l      |
|        |  | HDL-Cholesterin          |           | mmol/l      |
|        |  | Chol./HDL-Chol.-Quotient |           |             |
|        |  | LDL-Chol.Friedewald      |           | mmol/l      |
| 59 -   |  | Total Protein            | 64-83     | g/l         |
| 29 -   |  | Albumin                  | 35-52     | g/l         |
| 30     |  | Globuline                | 18-39     | g/l         |
| 8.2    |  | C-reakt.Protein          | <10.0     | mg/l        |
| 118 -  |  | LDH                      | 135-214   | U/l         |
| 58     |  | Creatinkinase            | 38-157    | U/l         |
|        |  | Troponin T hs (ng/L)     | <14       | ng/L        |
| 24     |  | Pankreas-Amylase         | 13-53     | U/l         |
|        |  | Glucose Fluorid          |           | mmol/l      |
|        |  | Glucose                  | 3.8-6.1   | mmol/l      |

# Case


- Sore throat, arthralgia, petechial skin rash
- Next step?
- Throat swab: Strep A rapid test positive
  - Therapy with Amoxycillin

# Case

- Dermatologic consult
  - Multiple partially confluent petechiae: Purpura



Skin punch biopsy:  
*leukocytoclastic vasculitis*



J A Carlson, Histopathology 56(1), 2010

# Leukocytoclastic vasculitis


- Small vessel vasculitis, broad differential diagnosis
  - Cutaneous small vessel vasculitis (idiopathic in 50%)
  - IgA vasculitis (Henoch-Schönlein Purpura)
  - Infection: HCV, HBV, bacterial infection
  - Drug induced (allopurinol, penicillin, sulfonamides, quinolones, thiazides, propylthiouracil, hydralazine etc)
  - Systemic diseases: RA, SLE, Colitis ulcerosa, M. Crohn
  - Systemic vasculitis: AAV



# Case

- ANA, ANCA, RF negative
- No signs of renal involvement
- Probably:  
**immune complex mediated vasculitis** associated with streptococcal infection
- Protracted course with persisting purpura and arthralgia
  - Steroid pulse 20mg/d with rapid response and resolution of symptoms

# Classification of vasculitis: Chapel Hill 2012



# Nomenclature

**Table 2.** Names for vasculitides adopted by the 2012 International Chapel Hill Consensus Conference on the Nomenclature of Vasculitides

---

**Large vessel vasculitis (LVV)**

Takayasu arteritis (TAK)

Giant cell arteritis (GCA)

**Medium vessel vasculitis (MVV)**

Polyarteritis nodosa (PAN)

Kawasaki disease (KD)

**Small vessel vasculitis (SVV)**

Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV)

Microscopic polyangiitis (MPA)

Granulomatosis with polyangiitis (Wegener's) (GPA)

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA)

**Immune complex SVV**

Anti-glomerular basement membrane (anti-GBM) disease

Cryoglobulinemic vasculitis (CV)

IgA vasculitis (Henoch-Schönlein) (IgAV)

Hypocomplementemic urticarial vasculitis (HUV) (anti-C1q vasculitis)

**Single-organ vasculitis (SOV)**

Cutaneous leukocytoclastic angiitis

Cutaneous arteritis

Primary central nervous system vasculitis

Isolated aortitis

Others

**Vasculitis associated with systemic disease**

Lupus vasculitis

Rheumatoid vasculitis

Sarcoid vasculitis

Others

**Vasculitis associated with probable etiology**

Hepatitis C virus–associated cryoglobulinemic vasculitis

Hepatitis B virus–associated vasculitis

Syphilis-associated aortitis

Drug-associated immune complex vasculitis

Drug-associated ANCA-associated vasculitis

Cancer-associated vasculitis

Others

# Types of vasculitis

- Primary Vasculitis
  - Systemic
  - Localised
- Secondary Vasculitis
  - Connective tissue diseases (Lupus, Sjögren..), RA, sarcoidosis
  - M. crohn, ulcerative colitis
  - Paraneoplastic
  - Infectious (HBV, HCV, HIV...)
  - Drug induced

# Nomenclature

| Category                | Disease Name                                          | Typical Vessel Type                         | Key Antibody Association                  | Main Clinical Features                                                  | Notes / Associations                                           |
|-------------------------|-------------------------------------------------------|---------------------------------------------|-------------------------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------|
| Immune complex-mediated | <b>IgA vasculitis (Henoch-Schönlein purpura)</b>      | Capillaries, venules                        | IgA immune complex deposition             | Palpable purpura (legs), arthralgia, abdominal pain, renal involvement  | Often follows infection (esp. upper respiratory)               |
| Immune complex-mediated | <b>Cryoglobulinemic vasculitis</b>                    | Capillaries, venules                        | Mixed cryoglobulins (IgM + IgG complexes) | Palpable purpura, arthralgia, peripheral neuropathy, glomerulonephritis | Associated with Hepatitis C, autoimmune disease                |
| Immune complex-mediated | <b>Anti-GBM disease (Goodpasture's)</b>               | Capillaries (especially in lungs & kidneys) | Anti-GBM antibodies                       | Pulmonary hemorrhage + rapidly progressive glomerulonephritis           | Linear IgG on immunofluorescence                               |
| Immune complex-mediated | <b>Hypersensitivity (leukocytoclastic) vasculitis</b> | Postcapillary venules                       | None specific (immune complexes)          | Palpable purpura, often drug-induced                                    | Commonly triggered by drugs, infections, or autoimmune disease |

# Nomenclature


| Category        | Disease Name                                                                            | Typical Vessel Type                              | Key Antibody Association  | Main Clinical Features                                                                                 | Notes / Associations                            |
|-----------------|-----------------------------------------------------------------------------------------|--------------------------------------------------|---------------------------|--------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| ANCA-associated | <b>Granulomatosis with polyangiitis (GPA)</b><br>(formerly Wegener's)                   | Small arteries, arterioles, venules, capillaries | c-ANCA (PR3-ANCA)         | Upper/lower respiratory tract involvement, sinusitis, pulmonary nodules, hematuria, glomerulonephritis | Granulomatous inflammation in respiratory tract |
| ANCA-associated | <b>Microscopic polyangiitis (MPA)</b>                                                   | Capillaries, venules, arterioles                 | p-ANCA (MPO-ANCA)         | Pulmonary capillaritis, rapidly progressive glomerulonephritis, skin purpura                           | No granulomas (unlike GPA)                      |
| ANCA-associated | <b>Eosinophilic granulomatosis with polyangiitis (EGPA)</b><br>(formerly Churg–Strauss) | Small arteries, venules                          | p-ANCA (MPO-ANCA) in ~40% | Asthma, eosinophilia, sinusitis, neuropathy, skin purpura                                              | Granulomatous + eosinophil-rich inflammation    |

# Clinical presentation

- General symptoms (especially with systemic vasculitis)
  - Fever
  - Fatigue
  - Weight loss
  - Arthralgia

# Clinical findings with small vessel vasculitis

- Purpura, splinter hemorrhage, ulcers, urticaria (cutaneous vasculitis)
- Cough, dyspnea, hemoptysis (GPA, MPA)
- Rhinitis with bloody crusts (GPA)
- Leg edema (glomerulonephritis) (GPA, MPA, cryoglobulinemic, IgA vasculitis)
- Red eye: episcleritis/scleritis (GPA)
- Arthritis (all forms of systemic vasculitis)
- Paresis (neuritis) (GPA, EGPA, cryoglobulinemic)





# History


- Characteristic symptoms
- Associated diseases
  - Infections: HBV, HCV, other viral, bacterial infections
  - Systemic rheumatic disease (SLE, RA etc)
- Drugs
  - Penicillin, sulfonamides, phenytoin, hydralazine, prophylthiouracil, minocyclin...
  - Cocain: Levamisol-induced vasculitis, ANCA positive

# Exams

- Physical examination: skin changes, internistic and neurologic exam)
- Lab tests
  - Routine lab (blood cells, chemistry, urine with protein analysis and sediment)
  - Immunoserology: rheumatoid factor, ANA, ANCA, complement, cryoglobulins
  - Infection serologies: HBV, HCV
- Imaging according to presentation


# Diagnosis

- Typical pattern of a specific vasculitis?
- Confirmation with tissue biopsy
  - Skin biopsy
  - Kidney biopsy
  - Nerve biopsy
  - ....



Kitching et al, Nat Rev Dis Prim 2020

# Diagnosis algorithm for purpura




# ANCA-associated vasculitis

- Heterogeneous group of small vessel vasculitis
  - Granulomatosis with polyangiitis (GPA, formerly Wegener): Incidence 0.4-12/10<sup>6</sup> ptyr
  - Microscopic polyangiitis (MPA): Incidence 0.5-23/10<sup>6</sup>
  - Eosinophilic granulomatosis with polyangiitis (EGPA, form. Churg-Strauss): 0.5-2.3/10<sup>6</sup> ptyr
- Characterised by presence of ANCA


# ANCA

- Immunofluorescence
  - C-ANCA, P-ANCA
- ELISA
  - Proteinase 3 (PR3)
  - Myeloperoxidase (MPO)
- cANCA and PR3 highly specific for GPA
- pANCA and MPO in 60-85% of MPA
- pANCA without MPO: nonspecific (also found in RA, SLE, IBD)
- ANCA partially correlate with disease activity




# ANCA associated vasculitis

## ■ Pathogenesis



# ANCA associated vasculitis


## ■ Pathogenesis: vascular injury








# ANCA associated vasculitis

## ■ Multiorgan manifestations




# Granulomatosis with polyangiitis (GPA)

- F/M 1:1, mean age 70, rarely before 50 yrs old
- Clinical presentation:
  - Upper respiratory tract: sinusitis, ulcerative rhinitis, saddle nose
  - Pulmonary: granulomas, hemorrhage
  - Glomerulonephritis (80% during course of disease)
  - Neurologic: mononeuritis multiplex, CNS-vasculitis
  - Ophthalmologic: retroorbital pseudotumour
  - Purpura
  - Arthralgia/-itis
- cANCA in 90% pos.



# GPA histology


- Vasculitis with necrosis
- Granulomatous inflammation
- Skin biopsy nonspecific
- Biopsy upper respiratory tract rarely diagnostic (nasal, sinus)
- Transbronchial biopsy in 25%, open lung biopsy in >50% diagnostic
- Kidney biopsy: focal, segmental GN
- Nerve biopsy (sural nerve)



# GPA prognosis

- Untreated high mortality (80% within 1 yr)
- with treatment survival >80% over 5 yrs

## All-cause




Early: 1997-2004  
Late: 2005-2012

# AAV therapy

- Induction therapy
  - 3-6 months: Induction of remission
- Maintenance therapy
  - 6-24 months
- Long term follow up
  - Indefinite
  - Retreatment in case of relapse

# AAV therapy



# AAV therapy


- Therapy dependent on the severity of the disease

**Table 2** Examples of organ/life-threatening and not organ/life-threatening manifestations in patients with AAV

| Examples of potentially organ/life-threatening manifestations*                                                                                                                                                                                                                                                  | Examples of manifestations that are not ultimately organ/life-threatening*                                                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|
| Glomerulonephritis                                                                                                                                                                                                                                                                                              | Nasal and paranasal disease without bony involvement (erosion) or cartilage collapse or olfactory dysfunction or deafness |
| Pulmonary haemorrhage                                                                                                                                                                                                                                                                                           | Skin involvement without ulceration                                                                                       |
| Meningeal involvement                                                                                                                                                                                                                                                                                           | Myositis (skeletal muscle only)                                                                                           |
| Central nervous system involvement                                                                                                                                                                                                                                                                              | Non-cavitating pulmonary nodules                                                                                          |
| Retro-orbital disease                                                                                                                                                                                                                                                                                           | Episcleritis                                                                                                              |
| Cardiac involvement                                                                                                                                                                                                                                                                                             |                                                                                                                           |
| Mesenteric involvement                                                                                                                                                                                                                                                                                          |                                                                                                                           |
| Mononeuritis multiplex                                                                                                                                                                                                                                                                                          |                                                                                                                           |
| *These are just examples of typical disease manifestations and many other manifestations of AAV exist. Assessment of severity in the individual patient may differ (eg, scleritis can become organ threatening under certain circumstances).<br>AAV, antineutrophil cytoplasmic antibody-associated vasculitis. |                                                                                                                           |



# AAV therapy






# AAV therapy

## Maintenance therapy in GPA

- RCT (MAINRITSAN): GPA in remission, randomised to Azathioprine vs Rituximab
- Outcome relapse rate



Guillevin et al, N Engl J Med 2014

# AAV therapy

- Glucocorticoid therapy
  - Initially high dose therapy
  - If contraindications: Avacopan (C5aR antagonist)

## Primary Efficacy Endpoints:

**BVAS = 0 at Week 26**  
(No GC in Prior 4 Weeks)

**BVAS = 0 at Week 52**  
(No GC in Prior 4 Weeks)

~300 patients: 1:1 Randomization

## Stratification:

1. Baseline Therapy:  
Oral/IV CYC or  
RTX

2. ANCA Type:  
Anti-MPO or  
Anti-PR3

3. New or Relapsing  
Disease


A.  
Active  
Drug  
Group



B.  
Standard  
of Care  
Group



\*over 20 weeks



Jayne et al, N Engl J Med 2021

# Summary

- Small vessel vasculitis can be primary or secondary as part of a systemic disease
- Look for characteristic clinical findings
  - Lab testing: specific auto-Ab (ANCA, ANA, RF)
- Diagnosis of vasculitis confirmed by biopsy
- Primary cutaneous small vessel vasculitis with good prognosis
- ANCA associated vasculitis can be life-threatening
  - referral to hospital
  - Intensive therapy needed

Grazie per l'attenzione

